Pfizer Inc. — Third Quarter 2026 Earnings Summary

Pfizer reported third-quarter 2026 revenues of $16.6 billion, reflecting a 32% operational growth in launched and acquired products despite a decline in COVID-19 related sales. The company raised its full-year 2026 revenue guidance to a range of $62.0 to $64.0 billion and adjusted diluted earnings per share guidance to $2.95 to $3.05. Key financial drivers included significant revenue increases for Eliquis, Padcev, and the Vyndaqel family, which offset declines in Comirnaty, Paxlovid, and the Prevnar family. Additionally, Pfizer appointed Cecile Guegan as Chief Financial Officer and announced multiple pipeline milestones, including FDA approvals for Talzenna and Tukysa.